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pathogenesis of schizophrenia as well as response to antipsychotic treatment have been reported. The objective of this study was to
determine whether refractory psychiatric symptoms in antipsychotic non-responders are related to polymorphisms in GRM3.
Methods Ninety-five treatment refractory schizophrenia participants were enrolled. Prior to a medication switch, global psychopathology
and negative symptoms were rated. These participants were genotyped for seven markers in GRM3. Genotype associations with symptoms
were assessed.
Results Two markers in GRM3 (rs1989796 and rs1476455), were associated with the presence of refractory global symptoms as measured
by the Brief Psychiatric Rating Scale (BPRS) Total scores. Participants with an rs1476455_CC genotype had significantly higher BPRS scores
than A-carriers (55.1 10.4 vs. 48.3 9.2; F¼ 7.6, p¼ 0.0071). Additionally, participants with the rs1989796_CC genotype had
significantly higher BPRS scores than T-carriers (50.1 5.7 vs. 55.8 10.5, F¼ 7.1, p¼ 0.0091). No evidence for significant associations
with negative symptoms was observed.
Conclusions Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in
persons with schizophrenia. Copyright # 2011 John Wiley & Sons, Ltd.key words — metabotropic; glutamate; antipsychotic; pharmacogenetics; schizophreniaINTRODUCTION
Glutamate disposition and signaling in the brain is
increasingly recognized as an essential component
of the pathogenesis and treatment of schizophrenia
(Harrison et al., 2008; Tamminga, 2006). Furthermore,
variants in glutamate system genes are associated with
cognitive function, medication response, medication
dosing, and in some studies with genetic risk for
schizophrenia (Bishop et al., 2005; Egan et al., 2004;
Fijal et al., 2009; Fujii et al., 2003). Efforts to identify
specific genetic variants that predict disease risk,
symptom presentation, and medication response in* Correspondence to: J. R. Bishop, The University of Illinois at Chicago
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Rm 164 (M/C 886), Chicago, IL 60612. Tel: 312-413-3495; Fax: 312-996-
0379; E-mail: jbishop@uic.edu
yPrior Publication: Portions of this research were presented as an abstract
and poster at the 2009 International Congress on Schizophrenia Research
Annual Meeting
Copyright # 2011 John Wiley & Sons, Ltd.psychiatric disorders have begun to focus on the
components of the glutamate system and are helping
to improve our understanding of the biology of
schizophrenia, risk for disease, and targets for new
drug treatments.
Many second generation antipsychotics have either
direct or indirect effects on the glutamate system that
may partially account for their mechanisms of action
and effectiveness in treating the cognitive and negative
symptoms of schizophrenia (Moghaddam, 2004; Tam-
minga, 2006). Investigational pharmacologic agents for
schizophrenia that stimulate selected metabotropic
glutamate receptors (mGluRs) as well as agents that
modulate N-methyl-D-aspartate (NMDA) receptors
have antipsychotic properties in both humans and
animal models of disease (Javitt, 2006; Patil et al.,
2007). Due to the complex nature of glutamate
signaling in the brain, including interactions with
dopamine and other neurotransmitter systems, genetic
variants in glutamate receptors are likely contributorsReceived 24 September 2010
Accepted 29 December 2010
GRM3 AND REFRACTORY SYMPTOMS IN SCHIZOPHRENIA 29to the variability seen in symptom presentation and
antipsychotic drug response (Bishop et al., 2005).
GRM3 has been localized to chromosome 7q21.1-
21.2 and spans 220.1 kb (Scherer et al., 1996). GRM3
codes for the mGluR3 protein which is a G-protein
coupled receptor. Along with the structurally similar
mGluR2 protein, mGluR3 is localized to the periphery
of both pre- and post-synaptic neurons and is essential
for optimal signaling of glutamate in the brain
(Cartmell and Schoepp, 2000). Initial studies of gene-
tic variation in GRM3 suggest association with
schizophrenia in some studies (Egan et al., 2004;
Fujii et al., 2003) but not others (Albalushi et al., 2008;
Bishop et al., 2007; Jonsson et al., 2009; Marti et al.,
2002; Norton et al., 2005; Schwab et al., 2008; Tochigi
et al., 2006).
In studies of cognition (Egan et al., 2004) and drug
response in schizophrenia (Bishop et al., 2005; Fijal
et al., 2009) GRM3 variants have accounted for a
portion of the variability seen in these outcome
measures. The mGluR3 receptor product of this gene
has subsequently become one glutamate receptor
targeted by potential antipsychotics (Patil et al.,
2007). The heterogeneity of the disease association
studies alongside growing evidence for the role of
GRM3 in cognition, symptom profile, and response
to drug treatment further suggests that variants in
this gene may influence disease presentation and
potentially interact with other genetic (Nicodemus
et al., 2007; Tan et al., 2007) and perhaps non-
genetic factors as opposed to being solely a disease risk
gene.
Collectively, research to date indicates that single
nucleotide polymorphisms (SNPs) in GRM3 may
be useful to study as genetic markers with potential
influence on response to antipsychotics in persons
with schizophrenia. In addition to traditional pharma-
cogenetic analyses of drug response, it is also
informative to identify and characterize the biological
underpinnings of antipsychotic non-response. Genetic
association studies of disease presentation and symp-
toms that are resistant to drug treatment may provide
important information on treatment strategies and
drug development efforts for difficult to treat patients.
Building on our initial research of treatment response
pharmacogenetics and disease association studies
of GRM3 in schizophrenia, we investigated the
relationship between variants in this gene with
symptomatology in a uniquely characterized cohort
of treatment refractory patients with the goal of
identifying genetic determinants of antipsychotic
resistant symptoms that may drive non-response to
initial therapies.Copyright # 2011 John Wiley & Sons, Ltd.METHODS
Participants
Ninety-five unrelated persons meeting DSM-IV
criteria for schizophrenia were recruited for this
study. Individuals were assessed in this study prior
to initiating treatment with a medication regimen for
treatment refractory schizophrenia (predominantly
clozapine). All participants gave written informed
consent to an IRB-approved protocol. Inclusion criteria
consisted of having a DSM-IV diagnosis of schizo-
phrenia, being at least 18 years of age, and refractory
to prior antipsychotic treatment according to the
operationally defined criteria of Kane et al. (1988) (i.e.,
persistent psychotic symptoms for at least 2 years
despite adequate separate trials with three antipsycho-
tic drugs from two biochemical classes at doses>1000
chlorpromazine equivalents for 6 weeks) (n¼ 93) or
inadequate response to at least two prior antipsychotic
agents (n¼ 2). Previously utilized second generation
antipsychotics were clinically estimated to exceed
>1000 equivalents (Woods, 2003). Participants were
recruited from inpatient and outpatient clinics in
this single site study. Potential subjects were excluded
if they had a DSM-IV diagnosis of organic mental
disorder, suicidal ideation, other serious medical con-
dition, or had previously been treated with clozapine.
Assessments
Participants were evaluated by a trained rater prior
to the initiation of their treatment refractory regimen.
with the 18-item Brief Psychiatric Rating Scale
(BPRS) with each item rated 1–7, with 1¼ not present
and 7¼ severe. In addition, ratings of negative symp-
toms were conducted with the Scale for Assessment of
Negative Symptoms (SANS), with SANS score defined
as the sum of the alogia, anhedonia, avolition, atten-
tion, and affective flattening global ratings with each
item rated 0–5, with 0¼ not present and 5¼ severe.
Genotyping
Genomic DNA was isolated from whole blood with
the salt precipitation method (Lahiri and Nurnberger,
1991). Genotyping was done with PyrosequencingTM
Technology. Polymerase chain reaction (PCR) primers
were designed using Oligo 6 (MBI, Cascade, CO,
USA). Pyrosequencing primers were designed using
Pyrosequencing Primer Design Version 1.01 software
(http://www.pyrosequencing.com). Seven SNPs (rs274622,
rs724226, rs917071, rs6465084, rs1468412, rs1989796,
and rs1476455) in GRM3 (Egan et al., 2004; FujiiHum. Psychopharmacol Clin Exp 2011; 26: 28–34.
DOI: 10.1002/hup
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BPRS or SANS scores. Genotyping assays for six of
the GRM3 variants were done as described previously
(Bishop et al., 2005). Assays for rs6465084 were
completed with 45 PCR cycles per reaction in a 50 ml
volume with 1.5 mM Mg2þ. PCR products were
visualized by electrophoresis on 1.5% agarose gels
stained with ethidium bromide prior to Pyrosequen-
cing. Forward, reverse, and Pyrosequencing primers
for the variants are as follows: rs6465084 (TTGCCTT
AATGACACAAAGTTCTC, CCGGTGCTCTTTCCA
TATTGA, and TCCATGAAAAAGGCAC). Genotyp-
ing was done blind to symptom ratings. All genotyping
assays were validated with direct sequencing.
Statistical analysis
Allele and genotype frequencies, Hardy–Weinberg
equilibrium (HWE), and genotype association tests
were conducted with PLINK software (Purcell et al.,
2007). Linkage disequilibrium (LD) plots were created
with Haploview version 4.2 software (Barrett et al.,
2005) (displayed as D’) with solid spine D’> 0.8 used
to define haplotype blocks (see Figure 1). Genotype
associations with BPRS and SANS scores as quanti-
tative traits were conducted with PLINK using the
genotypic (2df) association procedure which assesses
an additive effect model. The mperm 1000 permu-
tations option was selected to assess significance
by controlling for multiple genetic markers and the
LD between SNPs. Subsequent one-way Analysis of
Variance (ANOVA) tests were completed for markersFigure 1. Linkage disequilibrium structure GRM3
Copyright # 2011 John Wiley & Sons, Ltd.rs1989796, and rs1476455 which were identified as
significant from the PLINK procedures to quantify
differences across genotype groups. Student’s t-tests
were performed to test for differences in BPRS and
SANS scores between males and females. ANOVAwas
used to test for differences in SANS and BPRS scores
across racial groups. Pearson’s correlation coefficient
was used to examine relationships between age and
SANS/BPRS scores. Power calculations were carried
out using Quanto 1.2.4; http://hydra.usc.edu/gxe using
our lowest minor allele frequency (0.12 for rs1476455)
as a conservative estimate of our ability to detect
associations in this sample. At a minor allele frequency
of 0.12, using the means and standard deviations for
BPRS and SANS scores obtained in our study sample
of 95 subjects and a two-tailed 0.05 level of
significance for an additive effect model, we had
80% power to detect R2 for genotypes as low as 0.08
and a mean difference of difference of 2.65 points on
SANS and BPRS scores across genotype groups.
Policy and ethics
The work described in this article was carried out in
accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for
experiments involving humans.
RESULTS
Ninety-five participants with schizophrenia volun-
teered to take part in this study. Our study population
consisted of n¼ 85 (90%) Caucasian, n¼ 8 (8%)
African American, n¼ 1 (1%) Asian, and n¼ 1 (1%)
participants of unknown race. One participant was
Hispanic. Participants were predominantly male n¼ 61
(64%) with a mean age of 37.9 10.2 years. Mean
BPRS Total scores were in the moderately severe range
(53.5 10.5 points), as were negative symptoms as
measured by the SANS (13.9 4.3 points). In this
treatment refractory sample, age was not significantly
associated with BPRS or SANS scores and scores did
not differ across race/ethnic groups (all p’s> 0.05).
SANS scores were significantly higher in female
participants (15.1 4.3) versus males (13.2 4.2)
(t¼ 2.1, 1df, p¼ 0.04). BPRS scores did not differ
between males and females.
GRM3 genotypes
Allele and genotype frequencies are presented in
Table 1. Genotypes for GRM3 did not deviate from
HWE, with the exception of rs1468412 ( p¼ 0.024),Hum. Psychopharmacol Clin Exp 2011; 26: 28–34.
DOI: 10.1002/hup







rs274622 85917591 0.8154 0.34 (C) T:C 12/41/42
rs724226 85970025 0.4917 0.34 (A) G:A 13/39/43
rs917071 85998432 0.1928 0.34 (T) C:T 14/36/45
rs6465084 86048126 0.9842 0.28 (G) A:G 7/40/48
rs1468412 86078102 0.0313 0.35 (T) A:T 17/33/45
rs1989796 86118964 0.8735 0.37 (T) C:T 14/43/48
rs1476455 86196391 0.5059 0.12 (A) C:A 0/22/73
HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency.
Table 3. Genotype associations between type-3 metabotropic glutamate
receptor (GRM3) SNPs and negative symptom scores as assessed by the
Scale for Assessment of Negative Symptoms (SANS)a
SNP BETA SE R2 T-score p-value
Corrected
p-valueb
rs274622 0.65 0.64 0.011 1.01 0.32 1.0
rs724226 0.41 0.63 0.0045 0.64 0.52 0.90
rs917071 0.083 0.62 1.94E4 0.13 0.89 0.99
rs6465084 0.27 0.71 0.0016 0.38 0.70 1.0
rs1468412 0.14 0.59 6.30E4 0.24 0.81 1.0
rs1989796 0.59 0.64 0.0092 0.93 0.36 0.93
rs1476455 1.60 1.038 0.025 1.54 0.13 0.56
aAdditive model.
bPermuted p-value correcting for multiple comparisons and linkage dis-
equilibrium between SNPs.
GRM3 AND REFRACTORY SYMPTOMS IN SCHIZOPHRENIA 31which has been previously associated with risk for
schizophrenia (Egan et al., 2004). Markers in GRM3
were in moderate LD (denoted as D’) with one
haplotype block consisting of two SNPs with D’> 0.80
as indicated in Figure 1.
Relationship between symptoms and genetic
variability
Genotype associations between GRM3 variants and
BPRS and SANS scores are summarized in Tables 2
and 3. Two markers (rs1989796 and rs1476455) in
the 30 end of GRM3 were significantly associated
with BPRS Total scores, but not SANS scores. BPRS
and SANS scores across rs1989796 and rs1476455
genotype groups were then assessed. Mean (SD)
BPRS Total scores for rs1989796 CC, CT, and TT were
50.1 (10.0), 55.0 (9.9), and 58.2 (12.2) (F¼ 4.07, 2df,
p¼ 0.02). Participants with the rs1989796_CC geno-
type had significantly higher BPRS scores than T-
carriers (50.15.7 vs. 55.810.5, F¼ 7.1, p¼ 0.0091).
Mean (SD) BPRS scores for rs1476455 AC, and CC
were 48.3 (9.2) and 55.1 (10.4) (F¼ 7.6, 1df,
p¼ 0.007) (see Figure 2). Mean (SD) SANS scores
for rs1989796 CC, CT, and TT were 13.4 (4.0), 14.1Table 2. Genotype associations between type-3 metabotropic glutamate
receptor (GRM3) SNPs and total scores of the Brief Psychiatric Rating Scale
(BPRS)a
SNP BETA SE R2 T-score p-value
Corrected
p-valueb
rs274622 0.58 1.58 0.0015 0.37 0.71 1.0
rs724226 0.19 1.55 1.6E4 0.12 0.90 1.0
rs917071 1.93 1.50 0.018 1.29 0.20 0.69
rs6465084 0.67 1.73 0.0016 0.39 0.70 1.0
rs1468412 1.60 1.43 0.013 1.12 0.27 0.80
rs1989796 4.24 1.49 0.080 2.84 0.0055 0.04
rs1476455 6.79 2.47 0.075 2.75 0.0071 0.04
aAdditive model.
bPermuted p-value correcting for multiple comparisons and linkage dis-
equilibrium between SNPs.
Copyright # 2011 John Wiley & Sons, Ltd.(4.6), and 14.5 (4.2) (F¼ 0.44, 2df, p¼ 0.64). Mean
(SD) SANS scores for rs1476455 AC, and CC were
12.7 (4.3) and 14.3 (4.3) (F¼ 2.4, 1df, p¼ 0.13).
Adjusting these relationships with SANS scores for sex
did not alter the significance of these findings.
DISCUSSION
The principal finding of this study is that global
psychosis symptoms as measured by BPRS Total
scores were significantly related to two gene variants in
the 30 end of the GRM3 gene. Significant genotype
associations between rs1989796 and rs1476455 and
BPRS Total scores were observed, with potentially
clinically meaningful and statistically significant
differences across genotype groups. No significant
associations between GRM3 variants and negative
symptoms were observed in this study sample. To our
knowledge this is the first association between GRM3
variants and clinical symptoms in treatment refractory
schizophrenia.
Relationship of the glutamate system to
schizophrenia and antipsychotic pharmacology
Currently, there are eight known metabotropic
glutamate genes (GRMs) coding for mGluRs 1–8
one through eight (GRM1–GRM8). The eight individ-
ual mGluRs are subdivided into three groups (Group-I,
Group-II, and Group-III) based on amino acid seq-
uence and second messenger signaling similarities
(Nakanishi, 1992). GRM1 and GRM5 are the two
members of Group I, GRM2 and GRM3 comprise
Group II, with the rest falling into Group III. These
receptors mediate signal transduction through G-
protein second messenger systems which distinguishesHum. Psychopharmacol Clin Exp 2011; 26: 28–34.
DOI: 10.1002/hup
Figure 2. GRM3 variants and BPRS Total scores analysis of variance and Student’s t-tests were used to compare mean BPRS values standard deviation
across genotype groups
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alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propio-
nic acid (AMPA), and kainate receptors. mGluRs seem
to ‘‘fine tune’’ glutamate transmission, while iono-
tropic receptors regulate large scale glutamate fluctu-
ations in the brain (Conn and Pin, 1997).
A number of studies have investigated the relation-
ship between GRM3 and risk for schizophrenia with
mixed results. Collectively these data do not provide
strong evidence that variants in these genes on their
own confer an increased risk for developing this
disease. Previous investigations of GRM3 variants
as potential predictors of antipsychotic response in
schizophrenia (Bishop et al., 2005; Fijal et al., 2009)
while not associated with disease risk (Bishop et al.,
2007; Marti et al., 2002; Norton et al., 2005) suggests
that GRM3 variants are associated with drug response
and symptom presentation rather than the disease. The
results obtained from the cohort of treatment refractory
persons with schizophrenia studied here is consistent
with this possibility.
The primary mechanisms of action for antipsycho-
tics are hypothesized to center on striatal dopamine-2
(D2) and mesolimbic serotonin-2A (5HT2A) receptor
antagonism, but an increasing body of animal and
human research indicates that these agents may also
affect glutamate neurotransmission via regulating gene
expression (Girgenti et al., 2010; Molteni et al., 2009).
The relationship of genetic variability in the GRM3
region with the effects of second generation antipsy-
chotic medications is not surprising. Second generation
antipsychotics influence the expression of GRM3
mRNA as well as serum glutamate concentrations.
Serum glutamate concentrations increase significantly
after subjects are switched from conventional anti-
psychotic agents to olanzapine (Goff et al., 2002).
While not affecting NMDA or AMPA gene expression
in rats (Riva et al., 1997; Tascedda et al., 2001),Copyright # 2011 John Wiley & Sons, Ltd.clozapine and olanzapine appear to upregulate the
expression of GRM3 mRNA after chronic adminis-
tration. This upregulation may explain our earlier
results with rs274622 (Bishop et al., 2005) which is a
T/C variant residing in the ‘‘T’’ of a CCAAT box of
the GRM3 promoter region (Corti et al., 2001). This
variant may contribute to a state of glutamate hypo-
function that is reversed by antipsychotic treatment.
In the current study sample of treatment refractory
patients, we did not observe any associations between
SNPs in the 50 end of GRM3 with either negative or
global symptoms. This is not surprising, as the reasons
why an individual is refractory to antipsychotic agents
likely involve a number of variables. It is plausible that
these SNPs at the 30 end of the gene are in LD for
unstudied variants in the 30untranslated region of
GRM3, which may be targeted by epigenetic regulatory
mechanisms that have increased activity or importance
after long-term antipsychotic exposure, or which may
be general markers for treatment resistance.
These results may shed light on the heterogeneity
seen in studies investigating associations between
GRM3 and schizophrenia. At the current time, eleven
studies have investigated the association of GRM3
SNPs with schizophrenia, seven in Caucasian samples
and four in Asian samples (Albalushi et al., 2008;
Bishop et al., 2007; Chen et al., 2005; Egan et al.,
2004; Fallin et al., 2005; Fujii et al., 2003; Jonsson
et al., 2009; Marti et al., 2002; Norton et al., 2005;
Schwab et al., 2008; Tochigi et al., 2006). These
studies have resulted in mixed associations between
SNPs and/or haplotypes and disease. Additional
evidence suggests that GRM3 may interact with
the catechol-o-methyltransferase (COMT) Val158Met
variant to confer risk for schizophrenia (Nicodemus
et al., 2007; Tan et al., 2007). Our results may
provide additional insight into these heterogeneous
findings if there are differential relationships betweenHum. Psychopharmacol Clin Exp 2011; 26: 28–34.
DOI: 10.1002/hup
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subtypes.
Study limitations
This study describes the association of variation in one
candidate gene with symptoms in treatment refractory
schizophrenia patients prior to a medication switch.
The reasons for non-response to prior antipsychotic
treatment are unknown. Further, because of hetero-
geneity of prior antipsychotic treatment, we were unable
to determine the relationships of exposure to specific
agents and doses with the outcomes assessed in this
study. In addition, the long-standing nature of illness in
the subjects limited our ability to reliably estimate illness
duration. This study sample is predominantly Caucasian,
so we were unable to determine unequivocally whether
the relationships between GRM3 SNPs and symptom
presentation hold across other racial and ethnic groups.
Of note, our results did not change significantly when
non-Caucasian races were excluded from our analyses.
CONCLUSION
We observed that two variants in the 30 end of GRM3
were associated with global symptoms of psychosis as
assessed by the BPRS, but not negative symptoms in
this study sample. This suggests that variation in
GRM3 may be related to a mechanism of treatment
resistance in a subset of patients. However, it is
important to note that not all subjects with these
genotypes had higher measures of global psychosis
symptoms as measured by the BPRS; rather on average
they were higher across selected genotype groups. As
previously noted, there may be many reasons why a
patient has an inadequate response to antipsychotic
therapy. Dosing, treatment adherence, intolerance to
side effects, and agent selection are some modifiable
factors that may influence this outcome.
The identification of genetic biomarkers of
medication non-response is potentially useful, but
the interpretation of this information needs to be
considered carefully. However, it is conceivable that
the results of this type of study, if replicated, may be
useful in agent selection for schizophrenia. It is
plausible that the use of treatment strategies reserved
for later in treatment, such as clozapine, may be
considered earlier in therapy if we identify markers of
non-response to other therapeutic options.
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